Mizuho Begins Coverage on Audentes Therapeutics (BOLD)

Mizuho started coverage on shares of Audentes Therapeutics (NASDAQ:BOLD) in a research note issued to investors on Monday, MarketBeat reports. The firm issued a neutral rating and a $26.00 price target on the biotechnology company’s stock.

A number of other brokerages have also weighed in on BOLD. Raymond James Financial restated a hold rating on shares of Audentes Therapeutics in a report on Thursday, January 4th. William Blair restated a buy rating on shares of Audentes Therapeutics in a report on Friday, January 5th. BMO Capital Markets set a $44.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a report on Friday, January 5th. Zacks Investment Research lowered shares of Audentes Therapeutics from a hold rating to a sell rating in a report on Monday, January 22nd. Finally, Wedbush raised their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an outperform rating in a report on Thursday, January 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus target price of $34.00.

Shares of Audentes Therapeutics (NASDAQ:BOLD) opened at $32.82 on Monday. Audentes Therapeutics has a fifty-two week low of $13.90 and a fifty-two week high of $41.80.

In related news, Director Louis G. Lange sold 18,000 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $30.88, for a total value of $555,840.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, VP Suyash Prasad sold 8,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. 47.30% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of BOLD. Vanguard Group Inc. grew its position in shares of Audentes Therapeutics by 130.3% in the 2nd quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after buying an additional 383,837 shares during the last quarter. Farallon Capital Management LLC purchased a new position in shares of Audentes Therapeutics in the 4th quarter valued at $9,989,000. Citadel Advisors LLC grew its position in shares of Audentes Therapeutics by 206.2% in the 4th quarter. Citadel Advisors LLC now owns 339,588 shares of the biotechnology company’s stock valued at $10,612,000 after buying an additional 228,667 shares during the last quarter. Artal Group S.A. purchased a new position in shares of Audentes Therapeutics in the 3rd quarter valued at $5,602,000. Finally, BlackRock Inc. grew its position in shares of Audentes Therapeutics by 13.2% in the 4th quarter. BlackRock Inc. now owns 1,358,498 shares of the biotechnology company’s stock valued at $42,452,000 after buying an additional 158,576 shares during the last quarter. 64.94% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece was first published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another site, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/02/15/mizuho-begins-coverage-on-audentes-therapeutics-bold.html.

Audentes Therapeutics Company Profile

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Analyst Recommendations for Audentes Therapeutics (NASDAQ:BOLD)

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply